Consulta CRT-P; Percepta Bipolar CRT-P; Percepta Quadripolar CRT-P; Serena Bipolar CRT-P; Serena Quadripolar CRT-P; Sola
Medtronic, Inc. · Decision date Oct 3, 2025
What did the FDA decide?
FDA records P010015/S572 as a supplement to PMA P010015, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 3, 2025.
FDA approval order statement
updates to the medium rate battery manufacturing process
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 3, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P010015/S572
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic, Inc.
- Product code
- LWP
- Decision code
- OK30
- Decision date
- Oct 3, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implantable pulse generator, pacemaker (non-CRT).
- Applicant
- Medtronic, Inc.
- Product code
- LWP
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P010015. Subsequent supplements may change the device or its indications.
FDA decision timeline
P010015 · Original PMA
MEDTRONIC INSYNC(TM) BIVENTRICAL PACING SYSTEM
P010015/S567 · Related supplement
Consulta CRT-P (C4TR01); Syncra CRT-P (C2TR01)
P010015/S568 · Related supplement
Percepta Bipolar CRT-P, Percepta Quadripolar CRT-P, Serena Bipolar CRT-P, Serena Quadripolar CRT-P, Solara Bipolar CR T-
P010015/S569 · Related supplement
Consulta CRT-P C4TR01; Percepta Bipolar CRT-P W1TR01; Percepta Quadripolar CRT-P W4TR01; Serena Bipolar CRT-P W1TR02; Se
P010015/S570 · Related supplement
Percepta Bipolar CRT-P (W1TR01); Percepta Quadripolar CRT-P (W4TR01); Serena Bipolar CRTP (W1TR02); Serena Quadripolar C
P010015/S572 received
Application receipt date recorded by FDA.
P010015/S571 · Related supplement
Percepta Bipolar CRTP; Percepta Quadripolar CRT-P; Serena Bipolar CRT-P; Serena Quadripolar CRT-P; Solara Bipolar CRT-P;
P010015/S572 · FDA decision
30-Day Notice
P010015/S573 · Related supplement
Consulta CRT-P; Percepta Bipolar CRT-P; Percepta Quadripolar CRT-P; Serena Bipolar CRT-P; Serena Quadripolar CRT-P; Sola
P010015/S575 · Related supplement
Percepta Bipolar CRT-P W1TR01 NKE Percepta Quadripolar CRT-P W4TR01 NKE Serena Bipolar CRT-P W1TR02 NKE Serena Quadripol
P010015/S574 · Related supplement
Percepta Bipolar CRT-P W1TR01 NKE Percepta Quadripolar CRT-P W4TR01 NKE Serena Bipolar CRT-P W1TR02 NKE Serena Quadripol
P010015/S576 · Related supplement
Consulta CRT-P; Percepta Bipolar CRT-P; Percepta Quadripolar CRT-P; Serena Bipolar CRTP; Serena Quadripolar CRT-P; Solar
P010015/S577 · Related supplement
Percepta Bipolar CRT-P; Perceota Quadrioolar CRT-P; Serena Bipolar CRT-P; Serena Quadripolar CRT-P; Solara Bipolar CRT-P
P010015/S578 · Related supplement
Consulta CRT-P (C4TR01); Percepta Bipolar CRT-P (W1TR01); Percepta Quadripolar CRT-P (W4TR01); Serena Bipolar CRT-P (W1T
P010015/S579 · Related supplement
Attain OTW LV Lead; Consulta CRT-P; Percepta Bipolar CRT-P; Percepta Quadripolar CRT-P; Serena Bipolar CRT-P; Serena Qua
P010015/S580 · Related supplement
Consulta CRT-P C4TR01 Syncra CRT-P C2TR01
P010015/S582 · Related supplement
Percepta Bipolar CRT-P; Percepta Quadripolar CRT-P; Serena Bipolar CRT-P; Serena Quadripolar CRT-P; Solara Bipolar CRT-P
P010015/S584 · Related supplement
Percepta Bipolar CRT-P; Percepta Quadripolar CRT-P; Serena Bipolar CRT-P; Serena Quadripolar CRT-P; Solara Bipolar CRT-P
P010015/S586 · Related supplement
Attain Bipolar OTW Lead; Attain OTW L V Lead
P010015/S585 · Related supplement
Percepta Bipolar CRT-P (W1TR01); Percepta Quadripolar CRT-P (W4TR01); Serena Bipolar CRTP (W1TR02); Serena Quadripolar C
P010015/S581 · Related supplement
Percepta Bipolar CRT-P (W1TR01); Percepta Quadripolar CRT-P (W4TR01); Serena Bipolar CRT-P (W1TR02); Serena Quadripolar
P010015/S583 · Related supplement
Percepta Bipolar CRT-P (WlTR0l); Percepta Quadripolar CRT-P (W4TR01); Serena Bipolar CRT-P (WlTR02); Serena Quadripolar
P010015/S587 · Related supplement
Percepta Bipolar CRT-P, Percepta Quadripolar CRT-P, Serena Bipolar CRT-P, Serena Quadripolar CRT-P, Solara Bipolar CRT-P
P010015/S588 · Related supplement
Consulta CRT-P (C4TR01); Percepta Bipolar CRT-P (W1TR01); Percepta Quadripolar CRT-P (W4TR01); Serena Bipolar CRT-P (W1T
P010015/S589 · Related supplement
Percepta Bipolar CRT-P (W1TR01); Percepta Quadripolar CRT-P (W4TR01); Serena Bipolar CRT-P (W1TR02); Serena Quadripolar
P010015/S590 · Related supplement
Percepta Bipolar CRT-P, Percepta Quadripolar CRT-P, Serena Bipolar CRT-P, Serena Quadripolar CRT-P, Solara Bipolar CRT-P
P010015/S591 · Related supplement
Percepta Bipolar CRT-P (W1TR01); Percepta Quadripolar CRT-P (W4TR01); Serena Bipolar CRT-P (W1TR02); Serena Quadripolar
P010015/S592 · Related supplement
Percepta Bipolar CRT-P; Percepta Quadripolar CRT-P; Serena Bipolar CRT-P; Serena Quadripolar CRT-P; Solara Bipolar CRT-P
Timeline entries are records held by MedtechLedger for P010015. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P010015
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA approval | Aug 28, 2001 | FDA | |
Consulta CRT-P (C4TR01); Syncra CRT-P (C2TR01)P010015/S567 | Medtronic, Inc. | PMA supplement | Aug 6, 2025 | FDA |
| Medtronic, Inc. | PMA supplement | Aug 12, 2025 | FDA | |
| Medtronic, Inc. | PMA supplement | Aug 12, 2025 | FDA | |
| Medtronic, Inc. | PMA supplement | Sep 5, 2025 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 2, 2025 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 8, 2025 | FDA | |
| Medtronic, Inc. | PMA supplement | Dec 3, 2025 | FDA | |
| Medtronic, Inc. | PMA supplement | Dec 19, 2025 | FDA | |
| Medtronic, Inc. | PMA supplement | Jan 23, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Jan 23, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Feb 10, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Feb 10, 2026 | FDA | |
Consulta CRT-P C4TR01 Syncra CRT-P C2TR01P010015/S580 | Medtronic, Inc. | PMA supplement | Feb 12, 2026 | FDA |
| Medtronic, Inc. | PMA supplement | Mar 6, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Mar 27, 2026 | FDA | |
Attain Bipolar OTW Lead; Attain OTW L V LeadP010015/S586 | Medtronic, Inc. | PMA supplement | Apr 15, 2026 | FDA |
| Medtronic, Inc. | PMA supplement | Apr 23, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Apr 30, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | May 14, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Jul 16, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Jul 31, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Jul 31, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 5, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 23, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 29, 2026 | FDA |
Explore the linked device profile
Other records with product code LWP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Boston Scientific Corp | PMA supplement | Oct 3, 2026 | FDA | |
| Boston Scientific | PMA supplement | Oct 3, 2026 | FDA | |
| Boston Scientific Corp | PMA supplement | Jul 23, 2026 | FDA | |
| Boston Scientific | PMA supplement | Jul 23, 2026 | FDA | |
Assurity MRI / Endurity MRI PacemakersP140033/S101 | ABBOTT MEDICAL | PMA supplement | Jul 21, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 8200 Coral Sea St. N.E, Ms Mvs11, Mounds View, MN, 55112
Sources and methodology
- Original FDA record: P010015/S572
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





